These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27244474)

  • 1. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.
    Shatz W; Hass PE; Mathieu M; Kim HS; Leach K; Zhou M; Crawford Y; Shen A; Wang K; Chang DP; Maia M; Crowell SR; Dickmann L; Scheer JM; Kelley RF
    Mol Pharm; 2016 Sep; 13(9):2996-3003. PubMed ID: 27244474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics.
    Famili A; Crowell SR; Loyet KM; Mandikian D; Boswell CA; Cain D; Chan J; Comps-Agrar L; Kamath A; Rajagopal K
    Bioconjug Chem; 2019 Nov; 30(11):2782-2789. PubMed ID: 31553572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species.
    Freches D; Patil HP; Machado Franco M; Uyttenhove C; Heywood S; Vanbever R
    Int J Pharm; 2017 Apr; 521(1-2):120-129. PubMed ID: 28192159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
    Leong SR; DeForge L; Presta L; Gonzalez T; Fan A; Reichert M; Chuntharapai A; Kim KJ; Tumas DB; Lee WP; Gribling P; Snedecor B; Chen H; Hsei V; Schoenhoff M; Hale V; Deveney J; Koumenis I; Shahrokh Z; McKay P; Galan W; Wagner B; Narindray D; Hébert C; Zapata G
    Cytokine; 2001 Nov; 16(3):106-19. PubMed ID: 11741351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination.
    Pepinsky RB; Walus L; Shao Z; Ji B; Gu S; Sun Y; Wen D; Lee X; Wang Q; Garber E; Mi S
    Bioconjug Chem; 2011 Feb; 22(2):200-10. PubMed ID: 21254764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
    Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P
    J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.
    Nguyen A; Reyes AE; Zhang M; McDonald P; Wong WL; Damico LA; Dennis MS
    Protein Eng Des Sel; 2006 Jul; 19(7):291-7. PubMed ID: 16621915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.
    Koumenis IL; Shahrokh Z; Leong S; Hsei V; Deforge L; Zapata G
    Int J Pharm; 2000 Mar; 198(1):83-95. PubMed ID: 10722953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction.
    Caruso A; Füth M; Alvarez-Sánchez R; Belli S; Diack C; Maass KF; Schwab D; Kettenberger H; Mazer NA
    Mol Pharm; 2020 Feb; 17(2):695-709. PubMed ID: 31876425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye.
    Shatz W; Hass PE; Peer N; Paluch MT; Blanchette C; Han G; Sandoval W; Morando A; Loyet KM; Bantseev V; Booler H; Crowell S; Kamath A; Scheer JM; Kelley RF
    PLoS One; 2019; 14(6):e0218613. PubMed ID: 31251757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation.
    Patil HP; Freches D; Karmani L; Duncan GA; Ucakar B; Suk JS; Hanes J; Gallez B; Vanbever R
    J Control Release; 2018 Feb; 272():62-71. PubMed ID: 29247664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules.
    Crowell SR; Wang K; Famili A; Shatz W; Loyet KM; Chang V; Liu Y; Prabhu S; Kamath AV; Kelley RF
    Transl Vis Sci Technol; 2019 Nov; 8(6):1. PubMed ID: 31695962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
    Delgado C; Pedley RB; Herraez A; Boden R; Boden JA; Keep PA; Chester KA; Fisher D; Begent RH; Francis GE
    Br J Cancer; 1996 Jan; 73(2):175-82. PubMed ID: 8546903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.
    Schlapschy M; Theobald I; Mack H; Schottelius M; Wester HJ; Skerra A
    Protein Eng Des Sel; 2007 Jun; 20(6):273-84. PubMed ID: 17595342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigen-binding fragment (Fab').
    Roque C; Sheung A; Rahman N; Ausar SF
    Mol Pharm; 2015 Feb; 12(2):562-75. PubMed ID: 25548945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
    Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.
    Merdan T; Callahan J; Petersen H; Kunath K; Bakowsky U; Kopecková P; Kissel T; Kopecek J
    Bioconjug Chem; 2003; 14(5):989-96. PubMed ID: 13129403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation of antibody fragments for half-life extension.
    Jevševar S; Kusterle M; Kenig M
    Methods Mol Biol; 2012; 901():233-46. PubMed ID: 22723105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
    Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
    Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.